Small Molecules

26 Jun 2007 UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
26 Jun 2007 DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
26 Jun 2007 Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
26 Jun 2007 Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology
26 Jun 2007 Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia(R) in Children Suffering From Vernal Keratoconjunctivitis
26 Jun 2007 First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
26 Jun 2007 Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
26 Jun 2007 GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult
26 Jun 2007 New data from multiple studies show Galvus(R) delivers consistent and robust blood sugar control in patients with type 2 diabetes
26 Jun 2007 Metabasis Therapeutics Presents Preclinical Data on CS-917 and MB07811 at the American Diabetes Association Meeting
26 Jun 2007 Genaera Presents Preclinical Data On Trodusquemine (msi-1436) For The Treatment Of Obesity At The American Diabetes Association 67th Scientific Session
26 Jun 2007 Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
26 Jun 2007 Theravance Announces Positive Results from Phase 2 Clinical Study in Chronic Constipation with Investigational Compound TD-5108
26 Jun 2007 Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
26 Jun 2007 Molecular Insight Pharmaceuticals, Inc. Initiates First of Two Planned Pivotal Registration Trials for Zemiva(TM) in Detection of Cardiac Ischemia
26 Jun 2007 Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting
24 Jun 2007 Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
24 Jun 2007 Orexigen(TM) Therapeutics Reports Contrave(TM) Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes
24 Jun 2007 Takeda's Investigational DPP-4 Inhibitor Demonstrated Efficacy in Reducing Glucose Levels in Early Phase Study
23 Jun 2007 Rasilez(R), an important new treatment for high blood pressure, receives positive opinion recommending European Union approval
23 Jun 2007 Pfizer's Lyrica Receives FDA Approval for Fibromyalgia
22 Jun 2007 S*BIO becomes Singapore's first biotech company to initiate clinical trial of novel anti-cancer drug
22 Jun 2007 Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
22 Jun 2007 LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-Tacro for Organ Transplantation
22 Jun 2007 FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up